Targets › CLDN6
5 programs from 4 companies in 5 trials: 5 Phase 1; Oncology; next expected readout Jan 2027.
Plays a major role in tight junction-specific obliteration of the intercellular space..; FUNCTION: (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) entry into hepatic cells. (UniProt, P56747)
Open in Phaseline: the race on CLDN6, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| NovaRock Biotherapeutics | NBL-028 anti-CLDN6 antibody-drug conjugate | CLDN6 | Phase 1 | Advanced Solid Tumor | Jan 2027 |
| BeOne Medicines | BGB-B455 anti-CLDN6 antibody-drug conjugate | CLDN6 | Phase 1 | Advanced Solid Tumor | Apr 2028 |
| Context Therapeutics | CTIM-76 CLDN6-directed T cell-engaging bispecific antibody | CLDN6 | Phase 1 | Platinum-resistant Ovarian Cancer | May 2028 |
| BioNTech Cell & Gene Therapies | CLDN6 CAR-T CAR-T cell therapy targeting CLDN6 | CLDN6 | Phase 1 | Solid Tumor | Aug 2028 |
| BioNTech Cell & Gene Therapies | CLDN6 uRNA-LPX/CLDN6 modRNA-LPX RNA-based vaccine targeting CLDN6 | CLDN6 | Phase 1 | Solid Tumor | Aug 2028 |
Solid Tumor (2) Advanced Solid Tumor (2) Platinum-resistant Ovarian Cancer (1)
mixed (2), small molecule (2), antibody (1)
BioNTech Cell & Gene Therapies (2) Context Therapeutics (1) BeOne Medicines (1) NovaRock Biotherapeutics (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.